1. Right Ventricular Assist Device With Extracorporeal Membrane Oxygenation for Bridging Right Ventricular Heart Failure to Lung Transplantation: A Single-Center Case Series and Literature Review
- Author
-
Geun Dong Lee, Chuiyong Pak, Pil Je Kang, Sung-Ho Jung, Se Hoon Choi, Jae Guk Lee, Sang-Bum Hong, Dong Kyu Oh, and Ho Cheol Kim
- Subjects
Heart Failure ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Single Center ,medicine.disease ,Surgery ,Right Ventricular Assist Device ,Extracorporeal Membrane Oxygenation ,Treatment Outcome ,surgical procedures, operative ,Anesthesiology and Pain Medicine ,Respiratory failure ,Heart failure ,medicine ,Extracorporeal membrane oxygenation ,Humans ,Lung transplantation ,Heart-Assist Devices ,Cardiology and Cardiovascular Medicine ,Complication ,business ,Survival rate ,Lung Transplantation ,Retrospective Studies - Abstract
Objective Right ventricular heart failure (RVHF) is a critical complication in patients with respiratory failure, particularly among those who transitioned to lung transplantation using venovenous (VV) extracorporeal membrane oxygenation (ECMO). In these patients, both cardiac and respiratory functions are supported using venoarterial or venoarterial-venous ECMO. However, these modalities increase the risk of device-related complications, such as thromboembolism, bleeding, and limb ischemia, and they may disturb early rehabilitation. Due to these limitations, a right ventricular assist device with an oxygenator (Oxy-RVAD) using ECMO may be considered for patients with RVHF with VV ECMO. Design A retrospective case series and literature review. Setting A single tertiary care university hospital. Participants The study comprised lung transplantation candidates on ECMO bridging who developed right-sided heart failure. Interventions An RVAD with ECMO. Measurements and Main Results Of eight patients who underwent the study protocol, seven were bridged successfully to lung transplantation (BTT), and all patients with BTT were discharged, with a 30-day survival rate of 100% (7/7 patients). The 180-day survival rate was 85% (6/7 patients). Conclusions The study suggested that Oxy-RVAD using ECMO may be a viable option for bridging patients with RVHF to lung transplantation. Trial Registration Retrospectively registered.
- Published
- 2022